Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237
Fig 4
Alisertib-loaded intravaginal rings did not induce overt inflammation in the mouse vaginal tract.
FVB mice were either not implanted (control) or implanted with rings containing 1% (w/w) Alisertib in the vaginal tract. Intravaginal rings without Alisertib were used as the placebo. Mice were weighed daily over a week. Data is representative of the percentage of the mean weight at Day 0 ± standard error of mean (SEM) from five mice. Tissue sections of the mice genital tract were examined to any noticeable signs of abscess or inflammation in the (1) vaginal lumen, (2) epithelium and (3) lamina propria regions of the tissue. Tissues were collected at Day 7 and stained with H&E.